MNX Market Network Exchange
Commercial intelligence · New York
Menu
$1,000The New York strategy we build for retained clients, made accessible.Build my strategy →

Live · Open opportunity

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

National Institutes of Health

ShareLinkedIn ↗Email
Issuer
National Institutes of Health
Type
Federal funding opportunity
Jurisdiction
federal
Posted
September 25, 2026
Closes
November 16, 2029

Detail

The purpose of NEI's Translational Research program (TRP) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system.The TRP will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase can be up to two years and will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase can be up to four years and will support research that is in the final states of preclinical development with potential for near-term…

manufacturingfederalgrants.gov

View the full solicitation and how to apply ↗

Free account

Create a free account

Track New York opportunities and save searches across the Market. Free. No card required.

or email

Want a strategy to win work like this? Build your Market Network Strategic Plan →